Black Diamond Therapeutics Inc Total Assets
Black Diamond Therapeutics Inc total assets. Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) holds total assets worth $125.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Black Diamond Therapeutics Inc (BDTX) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Black Diamond Therapeutics Inc (2017–2025)
Total assets of Black Diamond Therapeutics Inc from 2017 to 2025. This chart illustrates how Black Diamond Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See BDTX stock price for real-time trading data and today's change.
Black Diamond Therapeutics Inc - Asset Composition Analysis
Black Diamond Therapeutics Inc Total Assets Breakdown (December 2025)
Black Diamond Therapeutics Inc total assets breakdown as of December 2025. Black Diamond Therapeutics Inc's total assets of $125.03 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Black Diamond Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Black Diamond Therapeutics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Black Diamond Therapeutics Inc's current assets represent 92.6% of total assets in 2025, a decrease from 98.7% in 2017.
- Cash Position: Cash and equivalents constituted 14.7% of total assets in 2025, down from 98.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Black Diamond Therapeutics Inc Competitors by Total Assets
Key competitors of Black Diamond Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Black Diamond Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.28 | 8.73 | 9.16 |
| Quick Ratio | 7.28 | 8.73 | 9.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $99.55 Million | $129.92 Million | $215.19 Million |
Black Diamond Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Black Diamond Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | 16.6% |
| Total Assets | $143.01 Million |
| Market Capitalization | $103.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Black Diamond Therapeutics Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Black Diamond Therapeutics Inc's assets grew by 16.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Black Diamond Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $143.01 Million | +16.61% |
| 2024-12-31 | $122.64 Million | -22.66% |
| 2023-12-31 | $158.57 Million | +1.48% |
| 2022-12-31 | $156.25 Million | -36.91% |
| 2021-12-31 | $247.68 Million | -24.87% |
| 2020-12-31 | $329.67 Million | +108.26% |
| 2019-12-31 | $158.29 Million | +205.44% |
| 2018-12-31 | $51.83 Million | +546.13% |
| 2017-12-31 | $8.02 Million | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more